Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, and its news flow reflects both internal pipeline progress and partner-driven milestones. The company regularly issues updates on its XmAb® drug candidates, including T-cell engaging bispecific antibodies and Fc-engineered antibodies that use its XmAb and Xtend™ technologies.
Investors following XNCR news can expect detailed announcements on clinical trial progress across oncology and autoimmune indications. Recent releases have covered Phase 1 and Phase 2 studies of programs such as XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for gynecologic and germ cell tumors, plamotamab for rheumatoid arthritis, XmAb657 for idiopathic inflammatory myopathies, and XmAb942 and XmAb412 for inflammatory bowel and other autoimmune diseases. These updates often include safety and efficacy summaries, dose-escalation status, and plans for pivotal or proof-of-concept studies.
Xencor’s news stream also features financial results and guidance, including quarterly earnings, cash and marketable securities levels, and commentary on how its balance sheet supports research and development plans. In addition, the company reports on intellectual property developments, such as U.S. patent issuances that extend royalty terms on Xtend-based antibodies like Ultomiris, and on collaboration milestones with partners including Amgen, Astellas, Incyte and Zenas Biopharma.
Corporate governance and strategic updates, such as board appointments and participation in investor conferences, are also common topics. For investors and analysts, the XNCR news page provides a centralized view of how Xencor’s XmAb technology platform is progressing in the clinic, how partnered programs are advancing, and how these activities translate into milestones, royalties and long-term development plans.
Xencor (NASDAQ:XNCR) announced that its licensee for Ultomiris informed Xencor it believes no additional U.S. royalties are owed and does not intend future U.S. payments, while continuing ex-U.S. payments. Xencor said it will seek resolution and conservatively updated cash runway to mid-2028.
The company reiterated issuance of U.S. Patent 12,492,253 and had previously expected an estimated $100–$120 million aggregate in low single-digit royalties from Ultomiris U.S. sales through 2028. Xencor expects $380–$400 million in cash and equivalents at year-end 2026.
Xencor (NASDAQ:XNCR) reported Q4 2025 and full-year results, highlighted by $610.8M in cash at year-end, Q4 revenue $28.2M and full-year revenue $125.6M. The company advanced multiple clinical programs including XmAb819 dose-expansion, XmAb942 Phase 2b enrollment, and plans for XmAb412 first-in-human in 2H26.
Guidance: Xencor expects year-end 2026 cash of $400–$430M and sufficient resources to fund operations through 2028. The company also estimates potential Xtend royalty revenue of $100–$120M through 2028.
Xencor (NASDAQ:XNCR) management will present at three investor conferences in early March 2026: TD Cowen on March 2, Leerink Partners on March 10, and Barclays on March 11.
Presentation times are listed in ET and PT. Live webcasts will be available under Events & Presentations on the company website, with replays accessible for at least 30 days.
Xencor (NASDAQ:XNCR) outlined 2026 corporate priorities and clinical milestones across five wholly owned XmAb® clinical-stage candidates. Key clinical readouts planned in 2026 include new data to support recommended Phase 3 doses for XmAb819 and XmAb541 in 2H26, Phase 1 updates for plamotamab and XmAb657 in 2H26, final Phase 1 healthy-volunteer results for XmAb942 in 1H26, and a first-in-human study start for XmAb412 in 2H26. Prior clinical results cited: XmAb819 showed a 25% partial response rate (20 evaluable patients) and a 70% disease control rate. Xencor ended Q4 2025 with approximately $611 million in unaudited cash, cash equivalents and marketable debt securities, which the company expects will fund operations through 2028.
Xencor (NASDAQ:XNCR) announced issuance of U.S. Patent 12,492,253 covering its Xtend™ Fc domain for C5-targeting antibodies, extending the U.S. patent term into December 2028—about three years longer than the prior latest-to-expire U.S. Xtend patent. Xencor expects to receive low-single-digit royalties on U.S. sales of Ultomiris (ravulizumab-cwvz) through December 2028.
The company estimates an additional $100–$120 million of potential royalty revenue for the extended term based on consensus Ultomiris sales forecasts. OMERS acquired royalties with annual caps up to $35 million for 2026–2028. Xencor recognized $51.0 million of non-cash royalty revenue for the nine months ended September 30, 2025.
Xencor (NASDAQ:XNCR) announced management will participate in two investor conferences in late 2025: the TD Cowen Immunology and Inflammation Virtual Summit on Wednesday, November 12, 2025 at 3:00 p.m. ET / 12:00 p.m. PT, and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET / 11:00 a.m. PT.
Both presentations will be available via live webcast under the company’s Investors & Events section at www.xencor.com. Replays will be posted on the Xencor website for at least 30 days after the events.
Xencor (NASDAQ:XNCR) reported third quarter 2025 results and clinical updates on November 5, 2025. Q3 revenue was $21.0M vs $17.8M year-ago. Cash, cash equivalents and marketable debt securities were $633.9M at September 30, 2025 and the company expects to end 2025 with $570M–$590M, providing runway into 2028. Net loss was $6.0M, or $(0.08) per share, versus $(0.72) in Q3 2024. Other income increased to $41.5M driven by unrealized gains.
Clinical: XmAb819 and XmAb541 showed early anti-tumor activity with planned recommended Phase 3 dose selection in 2026 and pivotal study starts in 2027; XmAb942 and plamotamab advanced into Phase 2b and Phase 1b studies, respectively.
Xencor (NASDAQ:XNCR) reported initial Phase 1 data for XmAb819, an ENPP3 x CD3 T-cell engager in development for advanced clear cell renal cell carcinoma (ccRCC), with results current as of Sept 19, 2025. Across 69 patients in 10 IV and 5 SC cohorts, XmAb819 showed a 25% overall response rate (5/20) and a 70% disease control rate (14/20) within the preclinically predicted target dose range. Safety was generally tolerable; common TEAEs included CRS, rash and GI events, mostly Grade 1–2. Notable safety signals: Grade 3 rash 16%, Grade 3 liver enzyme elevations 7%, one Grade 4 DLT (elevated liver enzymes), and no ICANS or Grade 5 events. Dose-expansion is underway and a recommended Phase 3 dose is expected to be selected during 2026.
Xencor (NASDAQ:XNCR) will host a live webcast and conference call on Friday, October 24, 2025 at 1:30 p.m. ET to discuss initial results from the ongoing Phase 1 dose‑escalation study of XmAb819, an ENPP3 x CD3 T‑cell engaging bispecific antibody for advanced clear cell renal cell carcinoma (ccRCC).
The same data will be presented as a poster at the AACR‑NCI‑EORTC Conference in Boston during Poster Session B on October 24, 12:30–4:00 p.m. ET (poster title: “Preliminary Phase 1 safety and antitumor activity of XmAb819…in patients with advanced ccRCC”).
The webcast is available via the company investor website and a recording will be posted for at least 30 days.
Xencor (NASDAQ:XNCR) will present initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3 bispecific) in patients with advanced clear cell renal cell carcinoma (ccRCC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The poster (Session: Poster Session B) is scheduled for Friday, October 24, 2025, 12:30–4:00 p.m. ET. Xencor submitted a placeholder abstract based on a prior data cut; full conference abstracts are due October 22, 2025 at 12:00 p.m. ET. An updated dataset with detailed safety analysis and efficacy from the target dose range will be presented when the conference embargo lifts. Management will host a webcast and conference call to discuss results; access details will be provided later.